Inactive Instrument

Cascadian Therapeutics Inc (USA) Share Price

Equities

Duration

Period

Style

Cascadian Therapeutics Announces 2018 Outlook and Recent Progress	04/01/18	GL
Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency	02/01/18	GL
Cascadian Therapeutics Added to the Nasdaq Biotechnology Index	13/12/17	GL
Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer	07/12/17	GL
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results	08/11/17	GL

Sector

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B